The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
CYSTADROPS (Recordati Rare Diseases Australia Pty Ltd)
Product name
CYSTADROPS
Date registered
Evaluation commenced
Decision date
Approval time
218 (255 working days)
Active ingredients
mercaptamine (cysteamine)
Registration type
EOI
Indication
CYSTADROPS (eye drop solution) is indicated for the treatment of corneal cystine deposits in adults and children with cystinosis.